色瑞替尼克服克唑替尼耐药用于一名伴有脑转移的ALK阳性非小细胞肺癌患者：病例报告

Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report.

作者信息

Zhu Zhouyu, Chai Ying

机构信息

Department of Thoracic Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

出版信息

Medicine (Baltimore). 2017 Nov;96(45):e8652. doi: 10.1097/MD.0000000000008652.

RATIONALE

The treatment of non-small cell lung cancer (NSCLC) has now changed dramatically in recent years and anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitors are developing rapidly.

PATIENT CONCERNS

Here we reported a 57-year-old ALK-positive NSCLC man with brain metastases.

DIAGNOSES

A case of lung adenocarcinoma with brain metastases.

INTERVENTIONS

Crizotinib was administered orally at a dose of 250mg twice a day until the brain metastases were found. Treatment with orally administered ceritinib at a dose of 450mg/d was initiated after crizotinib treatment.

OUTCOMES

The patient is currently receiving maintenance ceritinib treatment, with no evidence of extracranial or intracranial tumor progression for 25 months.

LESSONS

Ceritinib may be a good choice for ALK-positive NSCLC patients with brain metastases who acquire resistance to crizotinib.

理论依据

近年来，非小细胞肺癌（NSCLC）的治疗发生了巨大变化，间变性淋巴瘤激酶（ALK）抑制剂发展迅速。

患者情况

在此，我们报告了一名57岁的ALK阳性非小细胞肺癌男性患者，伴有脑转移。

诊断

一例肺腺癌伴脑转移。

干预措施

在发现脑转移之前，口服克唑替尼，剂量为250mg，每日两次。克唑替尼治疗后，开始口服色瑞替尼治疗，剂量为450mg/d。

结果

患者目前正在接受色瑞替尼维持治疗，25个月来无颅外或颅内肿瘤进展的证据。

经验教训

对于对克唑替尼产生耐药性的ALK阳性非小细胞肺癌脑转移患者，色瑞替尼可能是一个不错的选择。